The pathogenesis of immune checkpoint inhibitor (ICI)-colitis remains incompletely understood. We sought to identify key cellular driver(s) of ICI-colitis and their similarities to idiopathic ulcerative colitis (UC), and to determine potential novel therapeutic targets.